These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25333782)

  • 1. Chikungunya virus glycoproteins pseudotype with lentiviral vectors and reveal a broad spectrum of cellular tropism.
    Hu D; Zhang J; Wang H; Liu S; Yu L; Sun L; Qu Y
    PLoS One; 2014; 9(10):e110893. PubMed ID: 25333782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
    Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
    J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
    Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
    Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies.
    Venceslau-Carvalho AA; Teixeira de Pinho Favaro M; Ramos Pereira L; Rodrigues-Jesus MJ; Santos Pereira S; Andreata-Santos R; Dos Santos Alves RP; Castro-Amarante MF; Bitencourt Rodrigues K; Ramos da Silva J; Rahal Guaragna Machado R; Dos Passos Cunha M; Marinho de Andrade Zanotto P; Luzetti Fotoran W; Wunderlich G; Durigon EL; de Souza Ferreira LC
    Nanomedicine; 2021 Oct; 37():102445. PubMed ID: 34303841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate.
    Chung WC; Hwang KY; Kang SJ; Kim JO; Song MJ
    J Microbiol; 2020 Jan; 58(1):46-53. PubMed ID: 31768937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
    Chua CL; Sam IC; Merits A; Chan YF
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
    Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
    Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.
    Nor Rashid N; Teoh TC; Al-Harbi SJ; Yusof R; Rothan HA
    Trop Biomed; 2021 Mar; 38(1):36-41. PubMed ID: 33797522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
    Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
    Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection.
    Kumar P; Pok KY; Tan LK; Angela C; Leo YS; Ng LC
    J Virol Methods; 2014 Sep; 206():67-75. PubMed ID: 24880071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
    Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
    Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis.
    Kim J; Yang J; Kim YB; Lee HJ; Kim S; Poo H
    Virol Sin; 2019 Oct; 34(5):563-571. PubMed ID: 31214999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
    Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
    EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand.
    Nitatpattana N; Kanjanopas K; Yoksan S; Satimai W; Vongba N; Langdatsuwan S; Nakgoi K; Ratchakum S; Wauquier N; Souris M; Auewarakul P; Gonzalez JP
    Virol J; 2014 Oct; 11():183. PubMed ID: 25330992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.